Evotec's Partner Zhejiang Jingxin Pharmaceutical Secures Approval From Chinese Medical Authority For Evotec's Insomnia Drug, EVT201
Portfolio Pulse from Benzinga Newsdesk
Evotec's insomnia drug, EVT201, has received approval from the Chinese medical authority through its partner Zhejiang Jingxin Pharmaceutical. Evotec is set to receive double-digit royalties on net sales and additional milestones based on commercial success and potential sub-licensing.
December 06, 2023 | 7:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evotec's EVT201 approval in China could lead to increased revenues from royalties and milestones, positively impacting Evotec's financials.
The approval of EVT201 in China is a significant milestone for Evotec, directly affecting its revenue stream through royalties and potential milestones. This news is likely to be viewed positively by investors, as it opens up a large market for EVT201 and provides a new source of income.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Evotec's EVT201 approval in China could lead to increased revenues from royalties and milestones, positively impacting Evotec's financials.
The approval of EVT201 in China is a significant milestone for Evotec, directly affecting its revenue stream through royalties and potential milestones. This news is likely to be viewed positively by investors, as it opens up a large market for EVT201 and provides a new source of income.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100